IL15 and neoplasm: Another fourth generation CAR targeting VEGFR2 on the tumor vasculature and co-expressing murine IL-15 has been evaluated as a tool to overcome TME immunosuppression in immunocompetent, syngeneic melanoma-bearing mice.